{"id":"W4411628399","doi":"10.1016/j.esmoop.2025.105332","title":"70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpoints","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; BeiGene; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; European Commission; Seagen; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Mersana Therapeutics; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Nab-paclitaxel; Paclitaxel; Medicine; Ovarian cancer; Internal medicine; Oncology; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002055642,0.0004346397,0.001013345,0.0003016594,0.0002942148,0.0002647917,0.001277692,0.0002119996,0.003253471],"category_scores_gemma":[0.000240329,0.0003845623,0.0001450287,0.0007057536,0.0002268027,0.0007236161,0.0004084602,0.0004224071,0.0001404398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000185067,"about_ca_system_score_gemma":0.0006906393,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02377122,"about_ca_topic_score_gemma":0.00926962,"domain_scores_codex":[0.9958748,0.0004251989,0.001488846,0.0009997558,0.0005091274,0.0007023157],"domain_scores_gemma":[0.9978856,0.0003635959,0.0004603636,0.0009134655,0.0001903374,0.000186591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02176504,0.001582754,0.0007178992,0.0007321006,0.0002552147,0.0005898346,0.006578643,0.0001481273,0.9174077,0.02811082,0.01791657,0.004195307],"study_design_scores_gemma":[0.04441677,0.001250385,0.02421181,0.002003529,0.0002380813,0.0000413075,0.001822843,0.0004206517,0.8477832,0.01565891,0.06071827,0.001434249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9263656,0.0005778112,0.0002915791,0.001244449,0.001327805,0.001761346,0.003692756,0.0001003796,0.06463834],"genre_scores_gemma":[0.9900818,0.00007950706,0.002080142,0.0004697476,0.0001102849,0.0001848127,0.0001955609,0.00003777365,0.006760353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06962449,"threshold_uncertainty_score":0.9998606,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02590728600350213,"score_gpt":0.324439035187439,"score_spread":0.2985317491839369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}